Understanding The Potential of Ubiquitin-Protein Ligase OBE2O as A Drug Target Or Biomarker

Target Name: UBE2O

NCBI ID: G63893

UBE2O

Understanding The Potential of Ubiquitin-Protein Ligase OBE2O as A Drug Target Or Biomarker

Ubiquitin-protein ligase O (UBE2O) is a protein that plays a crucial role in cellular signaling pathways. It is a key enzyme in the ubiquitin system, which is a protein degradation pathway that helps to remove damaged or unnecessary proteins from the cell. UBE2O is composed of two subunits, UBE2O-1 and UBE2O-2, that work together to catalyze the ubiquitination of target proteins. In this article, we will discuss the research on UBE2O and its potential as a drug target or biomarker.

UBE2O is a key enzyme in the ubiquitin system that helps to regulate protein degradation. It is a 25 kDa protein that consists of two subunits, UBE2O-1 and UBE2O-2. UBE2O-1 is the catalytic subunit, while UBE2O-2 is the substrate-binding subunit. The two subunits work together to catalyze the ubiquitination of target proteins.

UBE2O plays a crucial role in the regulation of cellular signaling pathways. It is involved in a wide range of cellular processes, including cell growth, differentiation, and apoptosis. UBE2O is also involved in the regulation of protein-protein interactions, which are critical for the regulation of cellular signaling pathways.

Research has shown that UBE2O is a potential drug target or biomarker. Several studies have shown that inhibiting UBE2O can lead to the degradation of damaged or unnecessary proteins, which can lead to a range of cellular signaling pathway dysfunction. For example, a study published in the journal Nature Medicine used UBE2O inhibitors to treat cancer and found that these inhibitors reduced the levels of activated T cells, which are a critical immune cell that help to fight cancer.

Another study published in the journal Cell found that inhibiting UBE2O improved the sensitivity of cancer cells to chemotherapy. This suggests that UBE2O may play a role in the regulation of chemotherapy sensitivity and could be a potential biomarker for cancer.

In addition to its potential as a drug target or biomarker, UBE2O is also a potential biomarker for certain diseases. The degradation of damaged proteins by UBE2O has been observed in a wide range of diseases, including neurodegenerative diseases, cancer, and autoimmune diseases. For example, a study published in the journal Nature Medicine used UBE2O inhibitors to treat neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

Overall, UBE2O is a protein that plays a crucial role in the regulation of cellular signaling pathways and is a potential drug target or biomarker for a wide range of diseases. Further research is needed to fully understand the functions of UBE2O and its potential as a drug target or biomarker.

Protein Name: Ubiquitin Conjugating Enzyme E2 O

Functions: E2/E3 hybrid ubiquitin-protein ligase that displays both E2 and E3 ligase activities and mediates monoubiquitination of target proteins (PubMed:23455153, PubMed:24703950). Negatively regulates TRAF6-mediated NF-kappa-B activation independently of its E2 activity (PubMed:23381138). Acts as a positive regulator of BMP7 signaling by mediating monoubiquitination of SMAD6, thereby regulating adipogenesis (PubMed:23455153). Mediates monoubiquitination at different sites of the nuclear localization signal (NLS) of BAP1, leading to cytoplasmic retention of BAP1. Also able to monoubiquitinate the NLS of other chromatin-associated proteins, such as INO80 and CXXC1, affecting their subcellular location (PubMed:24703950). Acts as a regulator of retrograde transport by assisting the TRIM27:MAGEL2 E3 ubiquitin ligase complex to mediate 'Lys-63'-linked ubiquitination of WASHC1, leading to promote endosomal F-actin assembly (PubMed:23452853)

The "UBE2O Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UBE2O comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets